Company
Every investor coverage indicates participated in a round Synthesis Medchem raised.
Companies Synthesis Medchem acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Prof Andrew Wilks | Founder | Forbes Australia |
Stories naming Synthesis Medchem. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Profile of scientist-entrepreneur Andrew Wilks covering the GSK sale of his cancer molecule, his SYNthesis BioVentures fund's family-office backers, and portfolio plays including Aculeus Therapeutics.